II期临床-话题@MedSci

#II期临床#

478篇内容 | 2507人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1524967, encodeId=1909152496eff, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Front Oncol： PD-L1抑制剂durvalumab用于局部进展期食管和胃食管连接处腺癌术后辅助治疗的疗效：II期临床研究, objectType=article, longId=217312, objectId=e46321e31264, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e46321e31264, replyNumber=0, likeNumber=69, createdTime=2021-09-20, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e46321e31264, moduleTitle=Front Oncol： PD-L1抑制剂durvalumab用于局部进展期食管和胃食管连接处腺癌术后辅助治疗的疗效：II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e46321e31264)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524966, encodeId=53241524966f8, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=布美他尼用于自闭症III期临床试验失败, objectType=article, longId=217084, objectId=f94e21e084df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f94e21e084df, replyNumber=0, likeNumber=98, createdTime=2021-09-16, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f94e21e084df, moduleTitle=布美他尼用于自闭症III期临床试验失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f94e21e084df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524965, encodeId=633b152496510, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=2021年9月12日简报：云南新增本土确诊病例7例、福建莆田市累计发现6例确诊；第二代新冠疫苗已完成II期临床试验；66岁女科学家因mRNA疫苗获大奖, objectType=article, longId=216995, objectId=8c02216995b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c02216995b9, replyNumber=0, likeNumber=53, createdTime=2021-09-13, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c02216995b9, moduleTitle=2021年9月12日简报：云南新增本土确诊病例7例、福建莆田市累计发现6例确诊；第二代新冠疫苗已完成II期临床试验；66岁女科学家因mRNA疫苗获大奖, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c02216995b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524964, encodeId=ea2815249645f, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Gastric Cancer：帕博利珠单抗（Pembrolizumab）vs 紫杉醇治疗既往治疗过PD-L1阳性胃或胃食管连接处癌的疗效：III期临床研究KEYNOTE‑061的2年更新结果, objectType=article, longId=216988, objectId=2a7f21698850, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a7f21698850, replyNumber=0, likeNumber=34, createdTime=2021-09-13, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a7f21698850, moduleTitle=Gastric Cancer：帕博利珠单抗（Pembrolizumab）vs 紫杉醇治疗既往治疗过PD-L1阳性胃或胃食管连接处癌的疗效：III期临床研究KEYNOTE‑061的2年更新结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a7f21698850)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524963, encodeId=cbc51524963bb, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Lung Cancer：多西他赛vs多西他赛+厄洛替尼治疗复发晚期非鳞状非小细胞肺癌的疗效：III期临床研究NVALT-18, objectType=article, longId=216915, objectId=e8b0216915a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8b0216915a0, replyNumber=0, likeNumber=69, createdTime=2021-09-12, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8b0216915a0, moduleTitle=Lung Cancer：多西他赛vs多西他赛+厄洛替尼治疗复发晚期非鳞状非小细胞肺癌的疗效：III期临床研究NVALT-18, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e8b0216915a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524962, encodeId=f7431524962f7, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Liver Cnacer：mTOR抑制剂Temsirolimus联合索拉非尼治疗晚期肝细胞癌的疗效和安全性：II期临床研究, objectType=article, longId=216786, objectId=af4a216e8623, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af4a216e8623, replyNumber=0, likeNumber=36, createdTime=2021-09-09, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af4a216e8623, moduleTitle=Liver Cnacer：mTOR抑制剂Temsirolimus联合索拉非尼治疗晚期肝细胞癌的疗效和安全性：II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af4a216e8623)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524960, encodeId=2825152496025, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=恒瑞医药SHR0302片治疗斑秃II期临床达到主要研究终点, objectType=article, longId=216297, objectId=88e921629ef3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=88e921629ef3, replyNumber=0, likeNumber=0, createdTime=2021-08-27, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=88e921629ef3, moduleTitle=恒瑞医药SHR0302片治疗斑秃II期临床达到主要研究终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=88e921629ef3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524959, encodeId=a0dd152495996, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=科济药业发布2021年中期业绩自主研发 CAR-T候选品进入海外关键II期临床试验, objectType=article, longId=216260, objectId=c3532162608a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3532162608a, replyNumber=0, likeNumber=52, createdTime=2021-08-26, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3532162608a, moduleTitle=科济药业发布2021年中期业绩自主研发 CAR-T候选品进入海外关键II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c3532162608a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524961, encodeId=f190152496137, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=拜耳启动Elinzanetant III期临床研发项目OASIS，用于治疗更年期血管舒缩症状, objectType=article, longId=214643, objectId=e3b121464360, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3b121464360, replyNumber=0, likeNumber=134, createdTime=2021-07-24, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3b121464360, moduleTitle=拜耳启动Elinzanetant III期临床研发项目OASIS，用于治疗更年期血管舒缩症状, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e3b121464360)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524958, encodeId=5438152495813, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Nat Med：严重肥胖和代谢综合征患者的粪便微生物移植II期临床试验 , objectType=article, longId=213880, objectId=451f213880fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=451f213880fd, replyNumber=0, likeNumber=0, createdTime=2021-07-09, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=451f213880fd, moduleTitle=Nat Med：严重肥胖和代谢综合征患者的粪便微生物移植II期临床试验 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=451f213880fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524957, encodeId=fd5e152495e34, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=JAMA Psychiatry：Zuranolone治疗产后抑郁III期临床获得成功, objectType=article, longId=213850, objectId=35db213850ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35db213850ab, replyNumber=0, likeNumber=75, createdTime=2021-07-08, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35db213850ab, moduleTitle=JAMA Psychiatry：Zuranolone治疗产后抑郁III期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35db213850ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524956, encodeId=2b281524956c2, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Ann Oncol: Ribociclib联合氟维司群治疗HR+/HER2-晚期乳腺癌的疗效和安全性：III期临床研究MONALEESA-3的结果更新, objectType=article, longId=213384, objectId=18202133844d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18202133844d, replyNumber=0, likeNumber=142, createdTime=2021-06-29, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18202133844d, moduleTitle=Ann Oncol: Ribociclib联合氟维司群治疗HR+/HER2-晚期乳腺癌的疗效和安全性：III期临床研究MONALEESA-3的结果更新, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18202133844d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524955, encodeId=60e11524955d8, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=JAMA Oncol：术后放疗（PORT）治疗手术完全切除并完成术后辅助化疗的pIIIA-N2 NSCLC患者的疗效和安全性：III期临床研究PORT-C, objectType=article, longId=213343, objectId=818f213343eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=818f213343eb, replyNumber=0, likeNumber=40, createdTime=2021-06-29, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=818f213343eb, moduleTitle=JAMA Oncol：术后放疗（PORT）治疗手术完全切除并完成术后辅助化疗的pIIIA-N2 NSCLC患者的疗效和安全性：III期临床研究PORT-C, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=818f213343eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524954, encodeId=993a1524954f3, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=JCO: Ixazomi联合来那度胺+地塞米松治疗复发或难治性多发性骨髓瘤（RRMM）的最终分析结果：III期临床研究TOURMALINE-MM1, objectType=article, longId=212671, objectId=87bb2126e1d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=87bb2126e1d5, replyNumber=0, likeNumber=48, createdTime=2021-06-15, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=87bb2126e1d5, moduleTitle=JCO: Ixazomi联合来那度胺+地塞米松治疗复发或难治性多发性骨髓瘤（RRMM）的最终分析结果：III期临床研究TOURMALINE-MM1, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=87bb2126e1d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524953, encodeId=fa6e152495393, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=NEJM：5价脑膜炎奈瑟菌疫苗NmCV-5 II期临床研究获得成功, objectType=article, longId=212433, objectId=8b68212433dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b68212433dd, replyNumber=0, likeNumber=61, createdTime=2021-06-09, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b68212433dd, moduleTitle=NEJM：5价脑膜炎奈瑟菌疫苗NmCV-5 II期临床研究获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b68212433dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524952, encodeId=de9d15249527e, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=NEJM：Sotorasib治疗KRASp.G12C突变晚期非小细胞肺癌II期临床数据喜人, objectType=article, longId=212430, objectId=207d212430a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=207d212430a0, replyNumber=0, likeNumber=98, createdTime=2021-06-09, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=207d212430a0, moduleTitle=NEJM：Sotorasib治疗KRASp.G12C突变晚期非小细胞肺癌II期临床数据喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=207d212430a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524951, encodeId=f15d152495100, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Br J Cancer：帕唑帕尼与拓扑替康联合治疗转移性和不可切除性软组织肉瘤患者的II期临床研究, objectType=article, longId=212072, objectId=e36e2120e2eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e36e2120e2eb, replyNumber=0, likeNumber=97, createdTime=2021-06-01, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e36e2120e2eb, moduleTitle=Br J Cancer：帕唑帕尼与拓扑替康联合治疗转移性和不可切除性软组织肉瘤患者的II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e36e2120e2eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524948, encodeId=cd8e15249487c, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=J Thorac Oncol: Capmatinib治疗既往应用过MET抑制剂的肺癌的疗效：一项II期临床试验, objectType=article, longId=211358, objectId=b3ef2113580f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3ef2113580f, replyNumber=0, likeNumber=86, createdTime=2021-05-17, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3ef2113580f, moduleTitle=J Thorac Oncol: Capmatinib治疗既往应用过MET抑制剂的肺癌的疗效：一项II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b3ef2113580f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524947, encodeId=4ed7152494e5a, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=NEJM：TSLP单抗Tezepelumab治疗严重不受控制哮喘III期临床研究获得成功, objectType=article, longId=211275, objectId=f24b2112e55c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f24b2112e55c, replyNumber=0, likeNumber=64, createdTime=2021-05-15, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f24b2112e55c, moduleTitle=NEJM：TSLP单抗Tezepelumab治疗严重不受控制哮喘III期临床研究获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f24b2112e55c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524946, encodeId=e138152494670, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=III期临床FIGARO-DKD研究结果：拜耳非奈利酮在慢性肾病合并2型糖尿病患者中达到心血管首要复合终点, objectType=article, longId=210971, objectId=aae42109e1a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aae42109e1a9, replyNumber=0, likeNumber=92, createdTime=2021-05-10, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aae42109e1a9, moduleTitle=III期临床FIGARO-DKD研究结果：拜耳非奈利酮在慢性肾病合并2型糖尿病患者中达到心血管首要复合终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aae42109e1a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

II期临床

2020-05-29

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Front Oncol： PD-L1抑制剂durvalumab用于局部进展期食管和胃食管连接处腺癌术后辅助治疗的疗效：II期临床研究

2021-09-20

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

布美他尼用于自闭症III期临床试验失败

2021-09-16

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

2021年9月12日简报：云南新增本土确诊病例7例、福建莆田市累计发现6例确诊；第二代新冠疫苗已完成II期临床试验；66岁女科学家因mRNA疫苗获大奖

2021-09-13

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Gastric Cancer：帕博利珠单抗（Pembrolizumab）vs 紫杉醇治疗既往治疗过PD-L1阳性胃或胃食管连接处癌的疗效：III期临床研究KEYNOTE‑061的2年更新结果

2021-09-13

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Lung Cancer：多西他赛vs多西他赛+厄洛替尼治疗复发晚期非鳞状非小细胞肺癌的疗效：III期临床研究NVALT-18

2021-09-12

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Liver Cnacer：mTOR抑制剂Temsirolimus联合索拉非尼治疗晚期肝细胞癌的疗效和安全性：II期临床研究

2021-09-09

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

恒瑞医药SHR0302片治疗斑秃II期临床达到主要研究终点

2021-08-27

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

科济药业发布2021年中期业绩自主研发 CAR-T候选品进入海外关键II期临床试验

2021-08-26

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

拜耳启动Elinzanetant III期临床研发项目OASIS，用于治疗更年期血管舒缩症状

2021-07-24

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Nat Med：严重肥胖和代谢综合征患者的粪便微生物移植II期临床试验

2021-07-09

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

JAMA Psychiatry：Zuranolone治疗产后抑郁III期临床获得成功

2021-07-08

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Ann Oncol: Ribociclib联合氟维司群治疗HR+/HER2-晚期乳腺癌的疗效和安全性：III期临床研究MONALEESA-3的结果更新

2021-06-29

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

JAMA Oncol：术后放疗（PORT）治疗手术完全切除并完成术后辅助化疗的pIIIA-N2 NSCLC患者的疗效和安全性：III期临床研究PORT-C

2021-06-29

仁医06 (审核中...)

前往app查看评论内容

#II期临床#

JCO: Ixazomi联合来那度胺+地塞米松治疗复发或难治性多发性骨髓瘤（RRMM）的最终分析结果：III期临床研究TOURMALINE-MM1

2021-06-15

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

NEJM：5价脑膜炎奈瑟菌疫苗NmCV-5 II期临床研究获得成功

2021-06-09

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

NEJM：Sotorasib治疗KRASp.G12C突变晚期非小细胞肺癌II期临床数据喜人

2021-06-09

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Br J Cancer：帕唑帕尼与拓扑替康联合治疗转移性和不可切除性软组织肉瘤患者的II期临床研究

2021-06-01

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

J Thorac Oncol: Capmatinib治疗既往应用过MET抑制剂的肺癌的疗效：一项II期临床试验

2021-05-17

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

NEJM：TSLP单抗Tezepelumab治疗严重不受控制哮喘III期临床研究获得成功

2021-05-15

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

III期临床FIGARO-DKD研究结果：拜耳非奈利酮在慢性肾病合并2型糖尿病患者中达到心血管首要复合终点

2021-05-10

科室
- - 订阅+
  - 更多科室
工具
服务